Think Research Corporation (TSX-V:THNK) has announced the launch of its clinical trial Electronic Data Capture (EDC) platform at subsidiary BioPharma Services Inc.
The EDC launch creates a world-class application at BioPharma's Phase 1 sites in Toronto and St. Louis as the platform is expected to give BioPharma enhanced and superior capability to capture Phase 1 data quicker with higher data quality.
The platform will expedite clinical trial timelines, improve access to data for sponsors, and enable clients to shorten their drug development timelines to get therapeutics to the market faster.
READ: Think Research says its common shares have been approved for trading on the OTCQB Venture Market
The EDC platform will be moving into the system validation stage with live clinic data to meet Current Good Clinical Practice (cGCP) standards in Toronto and St. Louis.
"Our new EDC platform is leading edge in the Phase 1 clinical research space and has been designed to be easily adaptable and scalable for later stage clinical trials,” said Renzo DiCarlo, president of Clinical Research at BioPharma, in a statement.
“We believe our clients will be delighted by the technology investments we are making. This new digital application makes our Phase 1 clinics truly world class in the Phase 1 CRO industry segment."
Sachin Aggarwal, CEO of Think, added: "This new platform is part of the ongoing digital transformation of BioPharma that we announced as part of the acquisition in 2021. Think expects that the integration of technology into BioPharma's clinical research business will lead to cost savings. We are delivering a platform that will have a significant impact on the clinical research business."
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham